Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAmeriHealth Caritas RELiZORB Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1336

    Digestive enzyme cartridge

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1336 alerts

    Get alerted when Policy CCP.1336 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for RELiZORB in adult and pediatric members, including neonates and infants, with confirmed exocrine pancreatic insufficiency receiving ongoing enteral nutrition and pancreatic enzyme replacement therapy. Other uses are investigational and reviewed case by case.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyDigestive enzyme cartridge
    Policy CodePolicy CCP.1336
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionObtain prior authorization and submit documentation confirming the qualifying diagnosis, treatment status, and required response to therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage criteria were clarified to include adult and pediatric populations, including neonates and infants.

    The evidence review incorporated two international clinical-practice guidelines and a multicenter retrospective study of children receiving enteral formula through an immobilized lipase cartridge.

    Up to 6Cartridges allowed per 24 hours

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 daysInitial authorization duration
    180 daysReauthorization interval
    Adults and pediatricCovered age populations
    3Alternative covered services
    All other usesInvestigational uses

    Medical Necessity and Coverage Criteria

    Initial Coverage

    Initial coverage for RELiZORB is available when ALL of the following criteria are met:

    ALL of the following

    • The member is an adult or pediatric patient, including a neonate or infant, who is in stable health.
    • The member has confirmed exocrine pancreatic insufficiency.
    • The member is receiving ongoing enteral nutrition.
    • The member is receiving pancreatic enzyme replacement therapy.
    • The requested authorization is for no more than six single-use cartridges per 24-hour period.≤ 6 cartridges per 24 hours
    • The initial authorization period does not exceed 90 days.≤ 90 days

    Continuation Therapy

    Continuation therapy requires reauthorization every six months when ALL of the following criteria are met:

    ALL of the following

    • The member continues to meet the applicable initial coverage criteria for RELiZORB.
    • Documentation demonstrates continued weight gain.
    • Documentation demonstrates resolution of gastrointestinal symptoms.
    • The reauthorization period does not exceed 180 days.≤ 180 days

    All other uses of a digestive enzyme cartridge are considered investigational and will be reviewed on a case-by-case basis.

    Related Codes and Authorization Parameters

    Related enteral nutrition codesHCPCS
    B4149Blenderized natural foods with intact nutrients, 100 cal = 1 unit
    B4150Nutritionally complete with intact nutrients, 100 cal = 1 unit
    B4152Nutritionally complete, calorically dense (≥1.5 kcal/mL), 100 cal = 1 unit
    B4153Hydrolyzed proteins (amino acids/peptide chain), 100 cal = 1 unit
    B4154Special metabolic needs (excludes inherited diseases), 100 cal = 1 unit
    B4155Nutritionally incomplete/modular nutrients, 100 cal = 1 unit
    B4157Special metabolic needs for inherited disease of metabolism, 100 cal = 1 unit
    B4158-B4162Pediatric-specific enteral formulas (various types), 100 cal = 1 unit
    Initial cartridge quantity
    Initial quantityUp to six cartridges
    Cartridge typeSingle-use
    Measurement periodPer 24-hour period
    Initial authorization duration
    Initial authorizationUp to 90 days
    Applies toInitial authorization for RELiZORB
    Authorization typePrior authorization

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain prior authorization and observe quantity limits

    Prior authorization is required for RELiZORB. Initial authorization may cover up to six single-use cartridges per 24-hour period for up to 90 days; reauthorization occurs every six months (180 days).

    • Initial quantity: up to six single-use cartridges per 24-hour period.
    • Initial authorization duration: up to 90 days.
    • Reauthorization interval: every six months (180 days).
    Documentation Required

    Document the qualifying clinical criteria

    Submit documentation confirming that the member is in stable health and has confirmed exocrine pancreatic insufficiency, ongoing enteral nutrition, and ongoing pancreatic enzyme replacement therapy.

    • Stable health

    Clinical Background

    Exocrine pancreatic insufficiency occurs when the pancreas does not provide adequate digestive enzymes, particularly lipase. Insufficient lipase activity impairs the digestion and absorption of dietary fat, resulting in fat malabsorption and potentially contributing to steatorrhea, weight loss, gastrointestinal symptoms, and deficiencies of fat-soluble vitamins and other nutrients.

    Members with exocrine pancreatic insufficiency may require pancreatic enzyme replacement therapy or ongoing enteral nutrition to meet nutritional goals.

    Key Terms

    Exocrine pancreatic insufficiency
    DefinitionA condition characterized by deficiency of pancreatic digestive enzymes
    Effect on digestionImpaired digestion and absorption of nutrients, particularly fats
    Relevant enzymeLipase deficiency can result in inadequately hydrolyzed fats and clinically significant fat malabsorption
    RELiZORB
    DefinitionA cartridge filled with immobilized lipase enzyme covalently bound to polymeric beads
    System connectionFits between the infusion pump and the implanted feeding tube
    Function
    Policy Summary
    PayerAmeriHealth Caritas
    PolicyDigestive enzyme cartridge
    Policy CodePolicy CCP.1336
    Change TypeRevised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionObtain prior authorization and submit documentation confirming the qualifying diagnosis, treatment status, and required response to therapy.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaRelated Codes and Authorization ParametersAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    Reauthorization interval
    Reauthorization intervalEvery six months
    Equivalent duration180 days
    Required for continuationEvidence of continued weight gain and gastrointestinal symptom resolution
  1. Confirmed exocrine pancreatic insufficiency
  2. Ongoing enteral nutrition
  3. Ongoing pancreatic enzyme replacement therapy
  4. Documentation Required

    Document response for reauthorization

    For reauthorization, submit evidence of continued weight gain and gastrointestinal symptom resolution. Reauthorization is every six months (180 days).

    • Continued weight gain
    • Gastrointestinal symptom resolution
    Denial Risk

    Noncovered uses may require case-by-case review

    Uses other than the covered indication are considered investigational and will be reviewed on a case-by-case basis. Such uses may not meet coverage criteria.

    • Covered indication: members in stable health with confirmed exocrine pancreatic insufficiency who are receiving ongoing enteral nutrition and pancreatic enzyme replacement therapy.
    Denial Risk

    Demonstrate both required outcomes

    Reauthorization requires evidence of both continued weight gain and gastrointestinal symptom resolution. Failure to demonstrate either outcome creates a denial risk for continued coverage.

    • Continued weight gain must be demonstrated.
    • Gastrointestinal symptom resolution must be demonstrated.
    • Both outcomes are required for reauthorization.
    Hydrolyzes fats in enteral formula and is intended to mimic the function of lipase
    Fat malabsorption
    DefinitionInadequate digestion and absorption of dietary fat caused by insufficient lipase activity
    Clinical indicatorsSteatorrhea, continued weight loss, abdominal discomfort, abdominal bloating, and loss of appetite
    Nutritional consequencesLow circulating levels of micronutrients, lipoproteins, and fat-soluble vitamins